University of Dundee

Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population

Innes, Hamish; McDonald, Scott; Hayes, Peter; Dillon, John F; Allen, Sam; Goldberg, David

Published in:
Journal of Hepatology

DOI:
[10.1016/j.jhep.2016.08.004](https://doi.org/10.1016/j.jhep.2016.08.004)

Publication date:
2017

Licence:
CC BY-NC-ND

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Innes, H., McDonald, S., Hayes, P., Dillon, J. F., Allen, S., Goldberg, D., Mills, P. R., Barclay, S. T., Wilks, D., Valerio, H., Fox, R., Bhattacharyya, D., Kennedy, N., Morris, J., Fraser, A., Stanley, A., Bramley, P., & Hutchinson, S. J. (2017). Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. *Journal of Hepatology*, 66(1), 19-27. <https://doi.org/10.1016/j.jhep.2016.08.004>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

© 2016. This manuscript version is made available under
the CC-BY-NC-ND 4.0 license [http://
creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

TITLE: Mortality in hepatitis C patients who achieve a sustained viral response to treatment relative to the general population

AUTHORS: Hamish Innes^{1,2}, Scott McDonald^{1,2}; Peter Hayes³; John F Dillon⁴, Sam Allen⁵, David Goldberg^{1,2}, Peter R Mills⁶, Stephen T Barclay⁷, David Wilks⁸, Heather Valerio^{1,2}, Ray Fox⁹, Diptendu Bhattacharyya¹⁰, Nicholas Kennedy¹¹, Judith Morris¹², Andrew Fraser¹³, Adrian Stanley⁷, Peter Bramley¹⁴, and Sharon J Hutchinson^{1,2}

AFFILIATIONS:

- 1) School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK
- 2) Health Protection Scotland, Glasgow, UK
- 3) Royal Infirmary Edinburgh, Edinburgh, UK
- 4) Ninewells Hospital and Medical School, Dundee, UK
- 5) University Hospital, Crosshouse, UK
- 5) Royal Infirmary Edinburgh, Edinburgh, UK
- 6) Gartnavel General Hospital, Glasgow, UK
- 7) Glasgow Royal Infirmary, Glasgow, UK.
- 8) Western General Hospital, Edinburgh, UK
- 9) The Brownlee Centre, Glasgow, UK
- 10) Kirkcaldy Hospital, Fife, UK
- 11) Monklands Hospital, Lanarkshire, UK
- 12) Southern General Hospital , Glasgow, UK
- 13) Aberdeen Royal Infirmary, Aberdeen, UK
- 14) Stirling Royal Infirmary, Stirling, UK

OVERALL WORD COUNT: ~5,450 (inc introduction; methods; results; discussion and references)

CONFLICTS OF INTEREST: HI reports personal fees from Gilead, outside the submitted work. PH has received personal support from Roche, Janssen, MSD and Gilead. JD reports grants and personal

1 fees from Roche, grants and personal fees from MSD, grants and personal fees from Janssen, grants
2 and personal fees from Gilead, personal fees from BMS, grants from GSK, grants and personal fees
3 from Abbvie, outside the submitted work. DG reports personal fees from Abbvie, personal fees from
4 Gilead and MSD, outside the submitted work. SB reports personal fees from Abbvie, personal fees
5 from BMS, personal fees from Gilead, personal fees from Janssen, personal fees from MSD, outside
6 the submitted work; .RF reports receiving advisory board/speaker's fees from Janssen, Gilead, BMS,
7 Merck and Abbvie. NK reports participation in Advisory Boards for Gilead, Merck, Abbvie, and
8 Janssen, outside the submitted work. SH reports grants from Health Protection Scotland, during the
9 conduct of the study; personal fees from Abbvie, personal fees from Gilead, outside the submitted
10 work. All other authors have nothing to disclose.
11
12

13
14
15
16
17 FUNDING STATEMENT: This work was supported, in part, by funding from the Scottish
18 Government.
19
20
21

22
23 ROLE OF STUDY SPONSOR: The Scottish government had no involvement in the design of this
24 study; in the analysis and interpretation of data; in the writing of the report; and in the decision to
25 submit the article for publication.
26
27

28
29 AUTHOR'S CONTRIBUTIONS: HI carried out the statistical analyses and drafted the manuscript.
30 All authors were involved in the study design; collection of data; interpretation of data; and the
31 editing of the manuscript.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ABSTRACT

BACKGROUND: The number of people living with previous hepatitis-C infection that have attained a sustained viral response (SVR) is expected to grow rapidly. So far, the prognosis of this group relative to the general population is unclear.

METHODS: Individuals attaining SVR in Scotland in 1996-2011 were identified using a national database. Through record-linkage, we obtained cause-specific mortality data complete to Dec 2013. We calculated standardised-mortality-ratios (SMRs) to compare the frequency of mortality in SVR patients to the general population. In a parallel analysis, we used Cox regression to identify modifiable patient characteristics associated with post-SVR mortality.

RESULTS: We identified 1824 patients, followed on average for 5.2 years after SVR. In total, 78 deaths were observed. Overall, all-cause mortality was 1.9 times more frequent for SVR patients than the general population (SMR: 1.86; 95% CI:1.49-2.32). Significant cause-specific elevations were seen for death due to primary liver cancer (SMR: 23.50; 95% CI:12.23-45.16), and death due to drug-related causes (SMR: 6.58, 95%CI:4.15-10.45). Together these two causes accounted for 66% of the total excess death observed. All of the modifiable characteristics associated with increased mortality were markers either of heavy alcohol use or injecting drug use. Individuals without these behavioural markers (32.8% of cohort) experienced equivalent survival to the general population (SMR: 0.70; 95% CI:0.41-1.18)

CONCLUSIONS:

Mortality in Scottish SVR patients is higher overall than the general population. The excess was driven by death from drug-related causes and liver cancer. Health risk behaviours emerged as important modifiable determinants of mortality in this population.

LAY SUMMARY:

Patients cured of hepatitis C through treatment had a higher mortality rate overall than the general population. Most of the surplus mortality was due to drug-related causes and death from liver cancer. A history of heavy alcohol use and injecting drug use were associated with a higher mortality risk.

INTRODUCTION:

The use of direct acting antiviral drugs has led to vast improvements in the efficacy and tolerability of treatment for chronic hepatitis C virus (HCV) infection. [1,2] As a result, the number of previously-infected persons living with a sustained viral response (SVR) is likely to increase rapidly in the years ahead. It is important therefore to gain a better understanding of what an SVR means in terms of an individual's subsequent health. SVR is regarded as a "cure" by clinicians[3]; patients[4]; pharmaceutical companies [5,6]; and the lay media[7]. Whilst this is accurate in virological terms (i.e. SVR *does* represent a durable eradication of the virus from blood serum[8]), the extent to which SVR is a cure for other noted aspects of the hepatitis C condition – namely: liver fibrosis[9], hepatocellular carcinoma[10], increased all-cause mortality relative to the general population [11] and extrahepatic manifestations[12] - remains unclear. The object of this study was to evaluate the mortality rate aspect of this knowledge gap. Although we know that SVR patients have lower mortality rates than non-SVR patients [3, 13] we do not know how the mortality of this group compares to the general population. This is in contrast with other fields of medicine, such as oncology, where comparing patient survival against the general population is central to determining rates of cure [14, 15]

Thus far, only two studies have compared mortality in SVR patients to the general population. The first study was based on 192 SVR patients recruited from five tertiary liver clinics in Europe and Canada. [16] All patients had advanced fibrosis at baseline and the average age was 49 years. For this cohort, ten year survival - at 91.1% - was no different to survival in the general population. More recently, Bruno et al examined survival in 181 SVR patients recruited from five clinics in Italy.[17] All individuals in this cohort had compensated cirrhosis at baseline, and the average age was 59 years. Here too, ten year survival -at 90.9% - was comparable to the general population. These initial data are encouraging, nevertheless a question mark remains over how representative their findings are to the wider SVR population. Firstly because both studies were confined to patients with advanced fibrosis and did not include patients with milder disease (i.e. the group where the greatest burden of infection lies [18]). Secondly, because patients in both studies were recruited from potentially select clinics that may not be representative –either in terms of the patient case mix or the clinical care received – of all clinics administering therapy. Therefore, in this study we analysed mortality data from a large nationwide cohort of SVR patients in Scotland. Our objective was to compare cause-specific mortality in SVR patients to the underlying general population.

METHODS:

1. DATA SOURCES

1.1: DATA ON CAUSE-SPECIFIC MORTALITY RATES IN SVR PATIENTS

We used data from a previously-described [19] retrospective cohort of HCV infected patients treated in Scotland who began and terminated a course of interferon-based antiviral therapy between Jan 1996 and Dec 2010, respectively. This cohort was restricted to patients who were treatment-naïve, and who at the time of treatment, had compensated liver disease. It further excluded individuals with HIV or hepatitis B co-infection (the latter was inferred on the basis of surface antigen positivity). In total, 3385 individuals met these criteria of whom 1824 attained SVR and form the focus of this present analysis. Subsequent mortality data, specifically information on the date and the cause of death, were obtained through record linkage to the Scottish mortality register -see [16] for further details. We examined the following seven causes of death; death due to: (i) primary liver cancer, (ii) other liver disease (i.e. liver death not due to primary liver cancer), (iii) drug-related causes, (iv) external causes (referring mainly to death from accidents, homicide, and suicide), (v) all non-liver cancers, (vi) diseases of the circulatory system, (vii) and all other causes not listed above. We used the International Classification of Disease (ICD) code present in the underlying cause of death field to define these mortality categories; see eTable 1 for further details. Mortality rates were expressed in terms of person-years of follow-up. For each individual, we commenced follow-up at 9 months after antiviral treatment was stopped (thereby factoring in 6 months for SVR eligibility and a further 3 month grace period to physically receive the requisite SVR test), and ended follow-up at the date of mortality, or the date that our extract of the mortality register was complete until (31 Dec 2013).

1.2: DATA ON CAUSE-SPECIFIC MORTALITY RATES IN THE GENERAL POPULATION

We obtained a bespoke dataset from the General Registry Office Scotland of all deaths occurring in Scotland between 1996 and 2014, according to the underlying cause of death, the age at death, the calendar year of death, and the decedent's gender. We linked this dataset to mid-year Scottish population estimates to determine cause-specific mortality rates for the general population. We examined the same seven causes of death as for our SVR cohort and again used the ICD code present in the underlying cause of death field to define these categories (see eTable 1).

2: STATISTICAL ANALYSIS:

2.1: SURVIVAL IN SVR PATIENTS RELATIVE TO THE GENERAL POPULATION

2.1.1: TEN YEAR SURVIVAL FUNCTION

We calculated the Kaplan Meier survival function up to ten years after SVR, and juxtaposed this against the survival function for the general population according to the equivalent age, sex and calendar year distribution. We generated these curves both in relation to the total cohort (N=1824), and also specifically for SVR patients who had not received a diagnosis of cirrhosis at baseline (N=1717). Our rationale for focusing on this latter subgroup was that non-cirrhotic SVR patients tend to be discharged from clinical care and their liver-related mortality should be low.

2.1.2: STANDARDISED MORTALITY RATIOS

The SMR represents the ratio of the number of *expected* deaths (i.e. expected given general population mortality rates) to the number of *observed* deaths. We determined the standardised mortality ratio (SMR) adjusted for age, gender and calendar year. We calculated the SMR for all-cause mortality, as well as the SMR for each of the seven causes of death listed afore. As per our estimates of ten year survival, SMRs were determined both for all SVR patients, and also specifically for SVR patients who had not received a diagnosis of cirrhosis at baseline.

2.2 IDENTIFYING BASELINE FACTORS ASSOCIATED WITH POST-SVR MORTALITY

We used Cox regression to identify baseline patient characteristics associated with post-SVR mortality. The baseline factors we assessed were: (i) age group (<35yrs; 35-49 yrs; and 50yrs+); (ii) gender; (iii) diagnosis of liver cirrhosis; (iv) Charlson comorbidity index (CCI); (v) genotype; (vi) maximum alcohol consumption sustained for at least six months; (vii) intravenous drug use history; (viii) past hospitalisation for alcohol intoxication; (ix) past hospitalisation for violence-related injury; (x) past hospitalisation for drug intoxication; (xi) pre-treatment aspartate aminotransferase-to-platelet-ratio index (APRI); and (xii) pre-treatment gamma glutamyl transferase (GGT). Diagnosed liver cirrhosis refers to whether the patient had been diagnosed with liver cirrhosis by the time of SVR attainment. Diagnosis of liver cirrhosis in Scotland over this study period was made through a combination of biopsy; transient elastography; abdominal ultrasound; clinical examination; and routine liver function tests. Intravenous drug use history and maximum alcohol consumption were determined from data self-reported by the patient at the time of their liver clinic assessment. Maximum alcohol consumption was specifically defined as the highest level of alcohol use, sustained for six months or more, prior to being seen at the HCV treatment clinic. This was categorised as <21 units/week; 22-49 units/week and ≥ 50 units/week. Past hospitalisation for alcohol intoxication, violence-related injury and drug intoxication were determined from historical hospitalisation records dating back to Jan 1980. The ICD codes used to define these events are listed in eTable 2. We calculated the CCI to gauge each patient's comorbidity burden at baseline.[20] The CCI assigns a score of 1-6 for each comorbidity present, with a higher score denoting greater severity: A metastatic solid tumour, for example, carries a score of 6, renal disease carries a score of 2, whereas uncomplicated diabetes incurs a score of 1. The final CCI for an individual is the total of these scores.

We used historical hospitalization data dating back to January 1, 1980 to determine the presence/absence of the various comorbidities at baseline (as per the ICD codes set out by Quan et al [21]). We extracted all liver function tests recorded on the clinical database within 2 years of starting treatment. We calculated the mean aspartate aminotransferase level and mean platelet count in order to infer the APRI. We categorised APRI as <0.7 and ≥ 0.7 corresponding to the optimal cut off to distinguish individuals with mild fibrosis (i.e. Metavir F0-F1) from individuals with non-mild fibrosis (i.e. Metavir F2+) [22]. We further determined the mean level of GGT, given that this was previously found to be an important determinant of SVR attainment in Scotland. [23] Associations between these 12 baseline factors and all-cause mortality were calculated initially both in their crude unadjusted forms, and after adjustment for age group, gender, cirrhosis and CCI. As with our SMR analysis, associations were calculated separately both for all SVR patients, as well as specifically for SVR patients without a diagnosis of cirrhosis at baseline.

RESULTS:

1: DESCRIPTION OF THE SVR PATIENTS AT BASELINE:

In this cohort of 1824 SVR patients, the mean age was 40.7 years and most individuals were male (67.9%) - see Table.1. The median calendar period at baseline was 2008 (IQR:2006-2010). All patients had compensated liver disease. Liver cirrhosis was diagnosed in 5.8%, and 53.6% had an APRI score <0.7 (indicative of Metavir F0-F1) where this score was known. In terms of health risk behaviours, almost a fifth (18.1%) had a history of heavy alcohol use, and 58.6% reported ever injecting drugs. Further, 6.9%, 17.6% and 14.3% had a history of previous hospitalisation due to alcohol intoxication, violence-related injury and drug intoxication, respectively. A description of the overlap between health risk behaviour variables is provided in eTable 3.

2: MORTALITY EVENTS OCCURING AFTER SVR:

The total duration of follow up in our cohort was 10,915 person-years. The mean and median duration of follow-up time per patient was 5.2 years and 5.9 years, respectively. In all, 78 deaths were observed. Nine deaths were due to primary liver cancer (eight deaths of which were cases of hepatocellular carcinoma, and one was a case of intrahepatic bile duct cancer); seven deaths were due to other liver-related causes; 18 deaths were drug-related; 5 deaths were due to external causes; 16 deaths were from non liver cancers; 9 deaths were due to diseases of the circulatory system; and the remaining 14 deaths were from other causes. To note, lung cancer was the most common type of non-liver cancer death (N=7), whilst chronic obstructive pulmonary disease was the most common type of “other” death (N=4). Finally, the nine deaths from primary liver cancer occurred after a mean of 4.8 years of follow-up at ages ranging from 46-77 years.

3: SURVIVAL IN SVR PATIENTS RELATIVE TO THE GENERAL POPULATION

3.1: TEN YEAR SURVIVAL FUNCTION

For all SVR patients, ten year survival was 93.2% (95% CI: 91.2%-84.8%) versus 96.1% for the general population. For SVR patients without baseline cirrhosis, ten year survival was 94.6% (95% CI: 92.7 96.1), versus 96.3% for the general population (Fig.1).

3.2: ALL-CAUSE AND CAUSE-SPECIFIC STANDARDISED MORTALITY RATIOS:

The number of all-cause deaths that would have been expected in our SVR cohort given general population mortality rates was 42. Thus with 78 deaths actually observed, the overall SMR was 1.86 (95% CI: 1.49-2.32). When confining the analysis to patients that had not been diagnosed with liver cirrhosis at baseline, the SMR fell to 1.55 (95% CI: 1.20-2.01). In terms of cause-specific SMRs (see Table 2.), significant elevations were observed for death due to primary liver cancer and death due to

1 drug-related causes. The SMR for liver cancer was less pronounced in the subgroup of patients
2 without diagnosed cirrhosis at baseline (SMR: 9.02; 95% CI: 2.91-27.96), than in the entire SVR
3 cohort as a whole (SMR: 23.50; 95% CI: 12.23-45.16). In contrast, the SMR for drug related mortality
4 was comparable between all SVR patients (SMR: 6.58, 95% CI: 4.15-10.45), and SVR patients
5 without baseline cirrhosis (SMR: 6.90, 95% CI: 4.35-10.96). We did not see any statistically
6 significant differences in the SMRs for liver cancer mortality, all-cause mortality and drug mortality
7 according to age (see Figure 3[i]). Finally, no statistically significant elevations were noted for the
8 remaining cause-specific categories, including: other liver disease; external causes, diseases of the
9 circulatory system; and non-liver cancers.

16 4: THE ABSOLUTE CONTRIBUTION OF EACH CAUSE TO THE OVERALL EXCESS:

18 Drug-related mortality made the biggest absolute contribution to overall excess mortality (42% in all
19 SVR patients, and 75% in SVR patients without baseline cirrhosis). Primary liver cancer accounted
20 for 24% of the total excess in all SVR patients and 13% of the excess in SVR patients without
21 cirrhosis. Taken together, these two causes of death accounted for 66% of all excess deaths in the
22 SVR cohort as a whole, and 88% of all excess death in SVR patients without cirrhosis (see Fig.2). We
23 further examined the absolute contribution of primary liver cancer and drug-related mortality in all
24 SVR patients according to age during follow-up (see Figure 3[ii]). In the under 50s, drug-related
25 causes accounted for the majority of the excess death (53%), whilst the contribution of primary liver
26 cancer was minimal (<5%). Conversely, in the over 50s, most of the excess (54%) was due to liver
27 cancer, whilst drug-related mortality played a more minor role (accounting for only 26% of the
28 excess).

37 5: BASELINE FACTORS ASSOCIATED WITH ALL-CAUSE MORTALITY

40 Ten factors were significantly associated ($p<0.05$) with an increased risk of post-SVR mortality
41 following adjustment for age group and gender, cirrhosis and CCI; see Table.1. These were as
42 follows: older age; male gender; diagnosis of liver cirrhosis; high Charlson comorbidity score; past
43 alcohol consumption $\geq 50+$ units/wk sustained for six months or more; history of intravenous drug
44 use; past hospitalisation for alcohol intoxication; past hospitalisation for drug intoxication; and past
45 hospitalisation for violence-related injury, and APRI <0.7 .

51 6: POST-HOC ANALYSES: GENERATING A COMPOSITE SCORE FOR HEALTH RISK 52 BEHAVIOURS

55 The five modifiable factors associated with post-SVR mortality were as follows: 1. past alcohol
56 consumption $\geq 50+$ units/wk sustained for six months or more; 2. history of intravenous drug use; 3.
57 past hospitalisation for alcohol intoxication; 4. past hospitalisation for drug intoxication; and 5. past
58 past hospitalisation for violence-related injury.

hospitalisation for violence-related injury heavy alcohol use). In a post-hoc analysis, we generated a 4-point composite score based on the presence or absence of these five factors (see Fig.4). The intention was to create a proxy marker for health risk behaviours present during follow-up. We calculated SMRs for all-cause mortality according to this composite score and observed a strong dose-response relationship (p-value for trend, <0.001). Among all SVR patients with a score of zero (i.e. indicating the minimum level of health risk behaviour), the SMR was 0.70 (95% CI: 0.41-1.18), whereas for individuals with a score of 3 (i.e. the maximum score, indicating the highest level of health risk behaviour), the SMR was 6.19 (95% CI: 3.60-10.67). We also constructed a multivariate Cox regression model to assess the association between our behaviour score and the mortality hazard after adjusting for age, sex, cirrhosis, CCI and APRI (see Table 3). We observed a stepwise change in the mortality hazard according to behaviour score. Among all SVR patients, the hazard was 2.12 times (p=0.035) , 4.25 times (p<0.001), and 7.28 times (p<0.001) higher for individuals with a score of 1, 2 and 3, respectively, relative to individuals with a score of zero.

DISCUSSION:

MAIN FINDINGS:

The arrival of highly effective and tolerable antiviral regimens for chronic hepatitis C infection has set the stage for a rapid increase in the number of persons living with SVR. Yet, our present understanding of the prognosis that this “cured” population face is incomplete. Although we know that SVR patients exhibit superior mortality and morbidity rates relative to non-SVR patients [3, 13, 18], we know little about how these rates compare to the broader general population. In the present study, we followed 1824 SVR patients up for 5.2 years on average, and observed mortality rates in excess of the general population. Specifically, among all SVR patients, mortality rates were almost 2-fold higher (SMR: 1.86; 95% CI: 1.49-2.32), whilst among SVR patients without a diagnosis of cirrhosis at baseline - a group who on the whole will tend to be discharged from specialist care without further follow-up - mortality rates were 1.6-fold higher (SMR: 1.55; 95% CI: 1.20-2.01). Our cause-specific analyses (see Table 2 and Fig.2-3) demonstrated two important points. Firstly, that the overall excess was driven, in the main, by a higher than expected frequency of death from liver cancer and death from drug-related causes. Secondly, that the contribution of these two causes differed with respect to age. Drug-related mortality accounted for 53% of all excess death in the under 50s (in comparison, only 4.3% of the excess death was due to primary liver cancer). Conversely, death from liver cancer accounted for 54% of all excess death in the over 50s (whereas, in this age group, only 26% of the excess death was due to drug-related causes).

THE OCCURRENCE OF PRIMARY LIVER CANCER:

The largest cause-specific SMRs were seen with respect to primary liver cancer. In our SVR cohort as a whole, the risk of dying from liver cancer was more than 20 times greater than the general population (SMR: 23.50; 95% CI: 12.23-45.16). Notably, an excess risk of dying from liver cancer remained - SMR: 9.02; 95% CI: 2.91-27.96 - after excluding individuals with diagnosed liver cirrhosis at baseline. This result requires careful interpretation. On the one hand, it could lend support to previous observations that the risk of liver cancer after SVR is not confined to cirrhotic patients, but extends more widely to some patients at the pre-cirrhosis stage.[24-28] Alternatively, it may reflect a high level of undiagnosed liver cirrhosis in our cohort (indeed, the potential for this is appreciable, given that the majority of patients had no record of a liver biopsy or fibroscan being conducted in the two years prior to baseline – see eTable 4). To inform which interpretation is more valid, we reviewed the medical notes of the three “non cirrhotic” individuals who went on to develop primary liver cancer (involving two deaths from hepatocellular carcinoma and one from intrahepatic bile duct carcinoma). While two patients had indications of significant/severe fibrosis, none of the three would have met the definition of compensated cirrhosis currently adopted by NHS England (see Appendix A), despite all having the requisite tests to do so on at least one level (i.e. all three had an

APRI score and AST:ALT ratio pre-treatment; while one case had an ultrasound and another had a biopsy upon completion of therapy). Further, only one case was retained in on-going clinical follow-up post SVR, while the other two were discharged. More research is arguably needed to inform which SVR patients can be safely discharged, versus which patients would benefit from regular HCC screening. However, we must stress that although the *relative* risk of a liver cancer death was high in the non-cirrhotic group (i.e. nine times higher relative to the general population), the *absolute* risk – both of liver cancer and indeed of any liver-related event – was still very low (<1% after 7.5 years – see eFig.1).

PATIENT CHARACTERISTICS ASSOCIATED WITH POST-SVR MORTALITY:

To understand how the elevated mortality rate in “cured” hepatitis C patients might be reversed, we carried out a regression analysis to identify modifiable predictors of all-cause mortality (see Table.1). Ten predictive characteristics were identified in total, of which half – older age, male gender, liver cirrhosis; high CCI; and APRI <0.7 – were non-modifiable. But the remaining characteristics identified were markers of health risk behaviours (history of injecting drug use, history of heavy alcohol use, and past hospitalisation for violence, drug intoxication or alcohol intoxication) that, in principle at least, can be reversed. We created a composite score to approximate the degree of health risk behaviours present during follow-up (see Fig.4). The strong correlation between this composite score and the all-cause SMR suggests two things. Firstly, that health risk behaviours exert a strong influence on the extent to which mortality exceeds general population levels. Secondly, where health risk behaviours are minimal (i.e. as indicated by a score of zero) all-cause mortality rates are equivalent to and even lower than the general population.

From the non-modifiable predictors identified in this study, the increased mortality risk associated with APRI <0.7 (versus APRI ≥0.7) was unexpected and at first glance paradoxical – see Table 1. Subsequent interrogation revealed however that this association was very cause-specific, being driven only by an increased risk for drug mortality (see eFig.2). The association overall therefore is probably due to residual confounding. Mild disease will be associated with more recent acquisition of HCV (given that fibrosis increases with duration of infection), which in turn will be associated with active drug use. With more robust data on active drug use at baseline, we would therefore not expect an association with APRI<0.7 to persist.

CONSISTENCY WITH PREVIOUS WORK:

Our finding of higher mortality in SVR patients relative to the general population is not supported by two previous studies. In a cohort of 192 SVR patients with F3-F4 fibrosis and an average age of 49 years, Van der Meer et al observed a 10-year survival rate of 91.1%. [17] This was on par with survival in the general population. More recently, Bruno et al reported 10 year survival of 90.9% for

177 SVR cirrhotic patients with a mean age of 59 years. [18] Again, this 10-year survival was comparable to the general population. In contrast, for the present study, we followed up a much larger (N=1824), younger (mean age of 40.7 yrs) and more inclusive (comprising patients across the fibrosis continuum – not just those at an advanced end) group of SVR patients. Conversely, the 10-year survival that we observed of 93.2% was significantly lower than the 96.2% survival expected for the general population taking age, sex and calendar period into account. In overall terms, 86% more deaths were observed during our study than would have been expected under general population mortality rates (i.e. 78 deaths observed versus 42 expected). One possible explanation for the higher mortality rate in our study could be selection bias. The patients in our Scottish cohort represent the vast majority (80%+) of individuals attaining SVR in Scotland over the 1996-2011 time frame of this study. In contrast, the two previous studies were largely made up of individuals with biopsy-proven advanced liver fibrosis that attended a small number of tertiary clinics that may not accurately reflect the wider SVR population. Clearly more studies, from a variety of cohorts, are required to form a complete picture on this issue. Otherwise, our results concur with a prior analysis from Scotland reporting increased hospitalisation rates in SVR patients relative to the general population [29]. Our results are also consistent with a nationwide cohort study from Denmark. [30] In this study, Omland et al observed that individuals who clear HCV infection spontaneously (not via treatment albeit) had higher overall mortality than the general population. However, - in line with this study (see fig.4) - mortality was more comparable to the general population in subgroups without a history of alcohol and drug abuse.

LIMITATIONS OF THIS STUDY:

There are several limitations in this analysis to highlight. Cirrhosis was diagnosed in only 5.8% of patients at baseline, however due to inadequate testing, this is likely to be an underestimate of the true fraction with cirrhosis. Indeed, e-Table 4 shows that only 44% of patients received a liver biopsy or a fibroscan in the two years prior to SVR attainment, which highlights the lack of uniform cirrhosis surveillance in our cohort. Potentially, undiagnosed liver cirrhosis could explain why we observed six liver deaths in our non-cirrhotic group, albeit we think that this is unlikely because when we reviewed the medical notes of the 3 “non-cirrhotic” patients who developed liver cancer, we did not find anything to suggest that these individuals were cirrhotic in reality. Another limitation is that we had no information on the socioeconomic status of patients in this cohort. Because hepatitis C virus infection disproportionately affects people of lower socioeconomic status, and lower socioeconomic status is in turn associated with higher mortality rates [31], the omission of this variable could have inflated our survival differences. Thirdly, our data on health risk behaviours are limited in that they relate only to the baseline time point, and mostly focus on only the extremes of alcohol and drug use. Future studies correcting for these weaknesses and additionally examining the impact of other major health behaviours –tobacco smoking, physical activity and diet—would be valuable. Fourthly,

1 patients in our cohort were treated with either standard interferon ± ribavirin, or pegylated interferon ±
2 ribavirin. These regimens are long (16-48 weeks) and entail significant adverse effects. As a result,
3 patients would typically have received intensive coaching from clinicians and nursing staff (and this
4 coaching would have applied especially to SVR patients who, given futility stopping rules, remain in
5 the treatment window for longer than non-SVR patients). We have previously speculated that this
6 coaching and/or the euphoria of attaining SVR may have an important galvanising effect on patients
7 with regard to encouraging more salubrious health behaviours [19]. Thus, in the impending era of
8 highly tolerable, accessible and efficacious antiviral therapy– i.e. an era that will obviate the same
9 level of patient coaching and patient commitment – a very different post-SVR picture could emerge. It
10 will be important to repeat this analysis five years hence. Finally, we did not have robust data on
11 diabetes mellitus status and obesity despite these conditions being recognised determinants of liver
12 sequelae in the SVR population.[32]

21 SUMMARY:

23 In this large nationwide Scottish cohort, mortality in patients with a hepatitis C “cure” was higher than
24 the general population. The excess was mainly driven by death from liver cancer and death from
25 drug-related causes. Health risk behaviours emerged as the major modifiable risk factor for mortality
26 in this population underlining the importance of a multidisciplinary approach to HCV that addresses
27 lifestyle risk factors *in addition to* viral infection. On this note the SVR time-point may be a
28 particularly opportune moment to assess what other services and support the patient may be in need
29 of. To minimise the post-SVR risk of HCC, careful and prudent staging of liver fibrosis should be
30 performed prior to discharge to identify those patients who might benefit from regular screening.
31 Arguably, more research is needed to bottom out more precisely which SVR patients stand to benefit
32 from such surveillance. As a final aside, this analysis has bearing on the new WHO targets to cut
33 global death from hepatitis B and C by 10% before 2020, and by 65% by 2030 [33].

REFERENCES:

- [1] Pawlotsky J-M. New hepatitis C therapies: the toolbox, strategies and challenges. *Gastroenterology* 2014; 146:1176-1192.
- [2] Pawlotsky J-M, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. *J Hepatol* 2015; 62:S87-S99.
- [3] Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. *Clin Infect Dis* 2011;52(7):889-900.
- [4] "Pamela Anderson says: I'm cured of Hep C". Accessed December 2015. <http://www.thesun.co.uk/sol/homepage/showbiz/6732270/Pamela-Anderson-cured-of-Hepatitis-C.html>
- [5] Your moment to cure. Viekira homepage. Accessed January 2016. <https://www.viekira.com/>
- [6] I am hepatitis C cured. Sovaldi homepage. Accessed January 2016. <http://www.sovaldi.com/>
- [7] Hepatitis C virus can be cured in 12 weeks with drug course: study. Accessed December 2015. http://www.huffingtonpost.ca/2015/11/18/hepatitis-c-cure_n_8592704.html
- [8] Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. *Gastroenterology*. 2008; 135:821-9.
- [9] Thein H, Q Yi, Dore GJ, Krahm MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology* 2008; 48(2):418-31.
- [10] El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. *Hepatology* 2002;36:S74-S83.
- [11] Aspinall E, Hutchinson SJ, Janjua NS, Grebley J, Yu A, Alavi M, et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. *J Hepatol* 2015; 62:269-77.
- [12] Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. *Gastroenterology* 2015; 149:1345-60.
- [13] Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. *Clin Infect Dis*. 2015;61:730-740.

- [14] Lambert PC, Thompson JR, Weston CL, Dickman PW. Estimating and modelling the cure fraction in population-based cancer survival analysis. *Biostatistics* 2007; 8:576-94.
- [15] Del Maso L, Guzzinati S, Buzzoni C, Capocaccia R, Serraino D, Caldarella A, et al. Long-term survival, prevalence , and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. *Ann Oncol* 2014; 25:2251-60.
- [16] Van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. *JAMA* 2014; 312:1927-8.
- [17] Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustaeind virologic response is similar to the general population. *J Hepatol* 2016; 64: 1217-23.
- [18] Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat.* 2014; 21 Suppl 1: 34-59.
- [19] Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, et al. Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. *Hepatology* 2015;62:355-64.
- [20] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-383. 20.
- [21] Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43:1130-1139.
- [22] Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet-ratio index for the stage of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology* 2011;53:726-736.
- [23] Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. *Eur J Gastroenterol Hepatol* 2012;24:646-655.
- [24] Sewell JL, Stick KM, Monto A. Hepatocellularcarcinoma after sustained virologic response in hepatitis C patients with cirrhosis on a pretreatment liver biopsy. *Eur J Gastroenterol Hepatol.* 2009; 21:225-9.

- [25] Hirashima N, Mizokami M, Orito E, Koide T, Itazu I, Kamuda K, et al. Case report: development of hepatocellular carcinoma in a patients with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. *J Gastroenterol Hepatol*. 1996; 11:955-8.
- [26] Scherzer TM, Reddy KR, Wrrba F, Hofer H, Staufer K, Steindl-Munda P, et al. Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C. *J Viral Hepat*. 2008; 15: 659-65.
- [27] Tabibian JH, Landaverde C, Winn J, Geller SA, Nissen NN. Hepatocellular carcinoma in a hepatitis C patients with sustained viral response and no fibrosis. *Ann Hepatol*. 2009; 8:64-67.
- [28] Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. *J Gastroenterol Hepatol*. 2015; doi: 10.1111/jgh.13236
- [29] Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, et al. Excess liver-related morbidity of chronic hepatitis C patients who achieve a sustained viral response and are discharged from care. *Hepatology* 2011; 54:1547-58.
- [30] Omland LH, Christensen PB, Krarup H, Jepson P, Weis N, Sorensen HT, et al. Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study. *PLoS One*. 2011; 6:e22476.
- [31] Omland LH, Osler M, Jepsen P, Krarup H, Weis N, Christensen PB, et al. Socioeconomic status in HCV infected patients – risk and prognosis. *Clin Epidemiol* 2013; 5:163-72.
- [32] El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. *Hepatology* 2016; in press
- [33] Stephan Wiktor. Hepatitis B and C public policy association meeting: EU HCV Brussels, 17th February 2016. <http://www.hcvbrusselssummit.eu/material/summit-podcast> (accessed April 2016).

FIGURE LEGENDS:

Fig.1: Ten-year survival relative to the general population for: (i) all SVR patients; and (ii) SVR patients without cirrhosis.

Fig.2: Absolute contribution (%) to the overall excess for each cause of death, for (i) all SVR patients, and (ii) SVR patients without cirrhosis at baseline.

Fig.3: For all SVR patients: (i) cause-specific standardised mortality ratios according to age, and (ii) absolute contribution (%) to the overall excess for each cause of death, according to age.

Fig.4: Standardised mortality ratio according to baseline health risk behaviours, for (i) all SVR patients, and (ii) SVR patients without cirrhosis.

TITLE: Mortality in hepatitis C patients who achieve a sustained viral response to treatment relative to the general population

AUTHORS: Hamish Innes^{1,2}, Scott McDonald^{1,2}; Peter Hayes³; John F Dillon⁴, Sam Allen⁵, David Goldberg^{1,2}, Peter R Mills⁶, Stephen T Barclay⁷, David Wilks⁸, Heather Valerio^{1,2}, Ray Fox⁹, Diptendu Bhattacharyya¹⁰, Nicholas Kennedy¹¹, Judith Morris¹², Andrew Fraser¹³, Adrian Stanley⁷, Peter Bramley¹⁴, and Sharon J Hutchinson^{1,2}

AFFILIATIONS:

- 1) School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK
- 2) Health Protection Scotland, Glasgow, UK
- 3) Royal Infirmary Edinburgh, Edinburgh, UK
- 4) Ninewells Hospital and Medical School, Dundee, UK
- 5) University Hospital, Crosshouse, UK
- 5) Royal Infirmary Edinburgh, Edinburgh, UK
- 6) Gartnavel General Hospital, Glasgow, UK
- 7) Glasgow Royal Infirmary, Glasgow, UK.
- 8) Western General Hospital, Edinburgh, UK
- 9) The Brownlee Centre, Glasgow, UK
- 10) Kirkcaldy Hospital, Fife, UK
- 11) Monklands Hospital, Lanarkshire, UK
- 12) Southern General Hospital , Glasgow, UK
- 13) Aberdeen Royal Infirmary, Aberdeen, UK
- 14) Stirling Royal Infirmary, Stirling, UK

OVERALL WORD COUNT: ~5,450 (inc introduction; methods; results; discussion and references)

CONFLICTS OF INTEREST: HI reports personal fees from Gilead, outside the submitted work. PH has received personal support from Roche, Janssen, MSD and Gilead. JD reports grants and personal

1 fees from Roche, grants and personal fees from MSD, grants and personal fees from Janssen, grants
2 and personal fees from Gilead, personal fees from BMS, grants from GSK, grants and personal fees
3 from Abbvie, outside the submitted work. DG reports personal fees from Abbvie, personal fees from
4 Gilead and MSD, outside the submitted work. SB reports personal fees from Abbvie, personal fees
5 from BMS, personal fees from Gilead, personal fees from Janssen, personal fees from MSD, outside
6 the submitted work; .RF reports receiving advisory board/speaker's fees from Janssen, Gilead, BMS,
7 Merck and Abbvie. NK reports participation in Advisory Boards for Gilead, Merck, Abbvie, and
8 Janssen, outside the submitted work. SH reports grants from Health Protection Scotland, during the
9 conduct of the study; personal fees from Abbvie, personal fees from Gilead, outside the submitted
10 work. All other authors have nothing to disclose.
11
12

13
14
15
16
17 FUNDING STATEMENT: This work was supported, in part, by funding from the Scottish
18 Government.
19
20
21

22
23 ROLE OF STUDY SPONSOR: The Scottish government had no involvement in the design of this
24 study; in the analysis and interpretation of data; in the writing of the report; and in the decision to
25 submit the article for publication.
26
27

28
29 AUTHOR'S CONTRIBUTIONS: HI carried out the statistical analyses and drafted the manuscript.
30 All authors were involved in the study design; collection of data; interpretation of data; and the
31 editing of the manuscript.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ABSTRACT

BACKGROUND: The number of people living with previous hepatitis-C infection that have attained a sustained viral response (SVR) is expected to grow rapidly. So far, the prognosis of this group relative to the general population is unclear.

METHODS: Individuals attaining SVR in Scotland in 1996-2011 were identified using a national database. Through record-linkage, we obtained cause-specific mortality data complete to Dec 2013. We calculated standardised-mortality-ratios (SMRs) to compare the frequency of mortality in SVR patients to the general population. In a parallel analysis, we used Cox regression to identify modifiable patient characteristics associated with post-SVR mortality.

RESULTS: We identified 1824 patients, followed on average for 5.2 years after SVR. In total, 78 deaths were observed. Overall, all-cause mortality was 1.9 times more frequent for SVR patients than the general population (SMR: 1.86; 95% CI:1.49-2.32). Significant cause-specific elevations were seen for death due to primary liver cancer (SMR: 23.50; 95% CI:12.23-45.16), and death due to drug-related causes (SMR: 6.58, 95%CI:4.15-10.45). Together these two causes accounted for 66% of the total excess death observed. All of the modifiable characteristics associated with increased mortality were markers either of heavy alcohol use or injecting drug use. Individuals without these behavioural markers (32.8% of cohort) experienced equivalent survival to the general population (SMR: 0.70; 95% CI:0.41-1.18)

CONCLUSIONS:

Mortality in Scottish SVR patients is higher overall than the general population. The excess was driven by death from drug-related causes and liver cancer. Health risk behaviours emerged as important modifiable determinants of mortality in this population.

LAY SUMMARY:

Patients cured of hepatitis C through treatment had a higher mortality rate overall than the general population. Most of the surplus mortality was due to drug-related causes and death from liver cancer. A history of heavy alcohol use and injecting drug use were associated with a higher mortality risk.

INTRODUCTION:

The use of direct acting antiviral drugs has led to vast improvements in the efficacy and tolerability of treatment for chronic hepatitis C virus (HCV) infection. [1,2] As a result, the number of previously-infected persons living with a sustained viral response (SVR) is likely to increase rapidly in the years ahead. It is important therefore to gain a better understanding of what an SVR means in terms of an individual's subsequent health. SVR is regarded as a "cure" by clinicians[3]; patients[4]; pharmaceutical companies [5,6]; and the lay media[7]. Whilst this is accurate in virological terms (i.e. SVR *does* represent a durable eradication of the virus from blood serum[8]), the extent to which SVR is a cure for other noted aspects of the hepatitis C condition – namely: liver fibrosis[9], hepatocellular carcinoma[10], increased all-cause mortality relative to the general population [11] and extrahepatic manifestations[12] - remains unclear. The object of this study was to evaluate the mortality rate aspect of this knowledge gap. Although we know that SVR patients have lower mortality rates than non-SVR patients [3, 13] we do not know how the mortality of this group compares to the general population. This is in contrast with other fields of medicine, such as oncology, where comparing patient survival against the general population is central to determining rates of cure [14, 15]

Thus far, only two studies have compared mortality in SVR patients to the general population. The first study was based on 192 SVR patients recruited from five tertiary liver clinics in Europe and Canada. [16] All patients had advanced fibrosis at baseline and the average age was 49 years. For this cohort, ten year survival - at 91.1% - was no different to survival in the general population. More recently, Bruno et al examined survival in 181 SVR patients recruited from five clinics in Italy.[17] All individuals in this cohort had compensated cirrhosis at baseline, and the average age was 59 years. Here too, ten year survival -at 90.9% - was comparable to the general population. These initial data are encouraging, nevertheless a question mark remains over how representative their findings are to the wider SVR population. Firstly because both studies were confined to patients with advanced fibrosis and did not include patients with milder disease (i.e. the group where the greatest burden of infection lies [18]). Secondly, because patients in both studies were recruited from potentially select clinics that may not be representative –either in terms of the patient case mix or the clinical care received – of all clinics administering therapy. Therefore, in this study we analysed mortality data from a large nationwide cohort of SVR patients in Scotland. Our objective was to compare cause-specific mortality in SVR patients to the underlying general population.

METHODS:

1. DATA SOURCES

1.1: DATA ON CAUSE-SPECIFIC MORTALITY RATES IN SVR PATIENTS

We used data from a previously-described [19] retrospective cohort of HCV infected patients treated in Scotland who began and terminated a course of interferon-based antiviral therapy between Jan 1996 and Dec 2010, respectively. This cohort was restricted to patients who were treatment-naïve, and who at the time of treatment, had compensated liver disease. It further excluded individuals with HIV or hepatitis B co-infection (the latter was inferred on the basis of surface antigen positivity). In total, 3385 individuals met these criteria of whom 1824 attained SVR and form the focus of this present analysis. Subsequent mortality data, specifically information on the date and the cause of death, were obtained through record linkage to the Scottish mortality register -see [16] for further details. We examined the following seven causes of death; death due to: (i) primary liver cancer, (ii) other liver disease (i.e. liver death not due to primary liver cancer), (iii) drug-related causes, (iv) external causes (referring mainly to death from accidents, homicide, and suicide), (v) all non-liver cancers, (vi) diseases of the circulatory system, (vii) and all other causes not listed above. We used the International Classification of Disease (ICD) code present in the underlying cause of death field to define these mortality categories; see eTable 1 for further details. Mortality rates were expressed in terms of person-years of follow-up. For each individual, we commenced follow-up at 9 months after antiviral treatment was stopped (thereby factoring in 6 months for SVR eligibility and a further 3 month grace period to physically receive the requisite SVR test), and ended follow-up at the date of mortality, or the date that our extract of the mortality register was complete until (31 Dec 2013).

1.2: DATA ON CAUSE-SPECIFIC MORTALITY RATES IN THE GENERAL POPULATION

We obtained a bespoke dataset from the General Registry Office Scotland of all deaths occurring in Scotland between 1996 and 2014, according to the underlying cause of death, the age at death, the calendar year of death, and the decedent's gender. We linked this dataset to mid-year Scottish population estimates to determine cause-specific mortality rates for the general population. We examined the same seven causes of death as for our SVR cohort and again used the ICD code present in the underlying cause of death field to define these categories (see eTable 1).

2: STATISTICAL ANALYSIS:

2.1: SURVIVAL IN SVR PATIENTS RELATIVE TO THE GENERAL POPULATION

2.1.1: TEN YEAR SURVIVAL FUNCTION

We calculated the Kaplan Meier survival function up to ten years after SVR, and juxtaposed this against the survival function for the general population according to the equivalent age, sex and calendar year distribution. We generated these curves both in relation to the total cohort (N=1824), and also specifically for SVR patients who had not received a diagnosis of cirrhosis at baseline (N=1717). Our rationale for focusing on this latter subgroup was that non-cirrhotic SVR patients tend to be discharged from clinical care and their liver-related mortality should be low.

2.1.2: STANDARDISED MORTALITY RATIOS

The SMR represents the ratio of the number of *expected* deaths (i.e. expected given general population mortality rates) to the number of *observed* deaths. We determined the standardised mortality ratio (SMR) adjusted for age, gender and calendar year. We calculated the SMR for all-cause mortality, as well as the SMR for each of the seven causes of death listed afore. As per our estimates of ten year survival, SMRs were determined both for all SVR patients, and also specifically for SVR patients who had not received a diagnosis of cirrhosis at baseline.

2.2 IDENTIFYING BASELINE FACTORS ASSOCIATED WITH POST-SVR MORTALITY

We used Cox regression to identify baseline patient characteristics associated with post-SVR mortality. The baseline factors we assessed were: (i) age group (<35yrs; 35-49 yrs; and 50yrs+); (ii) gender; (iii) diagnosis of liver cirrhosis; (iv) Charlson comorbidity index (CCI); (v) genotype; (vi) maximum alcohol consumption sustained for at least six months; (vii) intravenous drug use history; (viii) past hospitalisation for alcohol intoxication; (ix) past hospitalisation for violence-related injury; (x) past hospitalisation for drug intoxication; (xi) pre-treatment aspartate aminotransferase-to-platelet-ratio index (APRI); and (xii) pre-treatment gamma glutamyl transferase (GGT). Diagnosed liver cirrhosis refers to whether the patient had been diagnosed with liver cirrhosis by the time of SVR attainment. Diagnosis of liver cirrhosis in Scotland over this study period was made through a combination of biopsy; transient elastography; abdominal ultrasound; clinical examination; and routine liver function tests. Intravenous drug use history and maximum alcohol consumption were determined from data self-reported by the patient at the time of their liver clinic assessment. Maximum alcohol consumption was specifically defined as the highest level of alcohol use, sustained for six months or more, prior to being seen at the HCV treatment clinic. This was categorised as <21 units/week; 22-49 units/week and ≥ 50 units/week. Past hospitalisation for alcohol intoxication, violence-related injury and drug intoxication were determined from historical hospitalisation records dating back to Jan 1980. The ICD codes used to define these events are listed in eTable 2. We calculated the CCI to gauge each patient's comorbidity burden at baseline.[20] The CCI assigns a score of 1-6 for each comorbidity present, with a higher score denoting greater severity: A metastatic solid tumour, for example, carries a score of 6, renal disease carries a score of 2, whereas uncomplicated diabetes incurs a score of 1. The final CCI for an individual is the total of these scores.

We used historical hospitalization data dating back to January 1, 1980 to determine the presence/absence of the various comorbidities at baseline (as per the ICD codes set out by Quan et al [21]). We extracted all liver function tests recorded on the clinical database within 2 years of starting treatment. We calculated the mean aspartate aminotransferase level and mean platelet count in order to infer the APRI. We categorised APRI as <0.7 and ≥ 0.7 corresponding to the optimal cut off to distinguish individuals with mild fibrosis (i.e. Metavir F0-F1) from individuals with non-mild fibrosis (i.e. Metavir F2+) [22]. We further determined the mean level of GGT, given that this was previously found to be an important determinant of SVR attainment in Scotland. [23] Associations between these 12 baseline factors and all-cause mortality were calculated initially both in their crude unadjusted forms, and after adjustment for age group, gender, cirrhosis and CCI. As with our SMR analysis, associations were calculated separately both for all SVR patients, as well as specifically for SVR patients without a diagnosis of cirrhosis at baseline.

RESULTS:

1: DESCRIPTION OF THE SVR PATIENTS AT BASELINE:

In this cohort of 1824 SVR patients, the mean age was 40.7 years and most individuals were male (67.9%) - see Table.1. The median calendar period at baseline was 2008 (IQR:2006-2010). All patients had compensated liver disease. Liver cirrhosis was diagnosed in 5.8%, and 53.6% had an APRI score <0.7 (indicative of Metavir F0-F1) where this score was known. In terms of health risk behaviours, almost a fifth (18.1%) had a history of heavy alcohol use, and 58.6% reported ever injecting drugs. Further, 6.9%, 17.6% and 14.3% had a history of previous hospitalisation due to alcohol intoxication, violence-related injury and drug intoxication, respectively. A description of the overlap between health risk behaviour variables is provided in eTable 3.

2: MORTALITY EVENTS OCCURING AFTER SVR:

The total duration of follow up in our cohort was 10,915 person-years. The mean and median duration of follow-up time per patient was 5.2 years and 5.9 years, respectively. In all, 78 deaths were observed. Nine deaths were due to primary liver cancer (eight deaths of which were cases of hepatocellular carcinoma, and one was a case of intrahepatic bile duct cancer); seven deaths were due to other liver-related causes; 18 deaths were drug-related; 5 deaths were due to external causes; 16 deaths were from non liver cancers; 9 deaths were due to diseases of the circulatory system; and the remaining 14 deaths were from other causes. To note, lung cancer was the most common type of non-liver cancer death (N=7), whilst chronic obstructive pulmonary disease was the most common type of “other” death (N=4). Finally, the nine deaths from primary liver cancer occurred after a mean of 4.8 years of follow-up at ages ranging from 46-77 years.

3: SURVIVAL IN SVR PATIENTS RELATIVE TO THE GENERAL POPULATION

3.1: TEN YEAR SURVIVAL FUNCTION

For all SVR patients, ten year survival was 93.2% (95% CI: 91.2%-84.8%) versus 96.1% for the general population. For SVR patients without baseline cirrhosis, ten year survival was 94.6% (95% CI: 92.7 96.1), versus 96.3% for the general population (Fig.1).

3.2: ALL-CAUSE AND CAUSE-SPECIFIC STANDARDISED MORTALITY RATIOS:

The number of all-cause deaths that would have been expected in our SVR cohort given general population mortality rates was 42. Thus with 78 deaths actually observed, the overall SMR was 1.86 (95% CI: 1.49-2.32). When confining the analysis to patients that had not been diagnosed with liver cirrhosis at baseline, the SMR fell to 1.55 (95% CI: 1.20-2.01). In terms of cause-specific SMRs (see Table 2.), significant elevations were observed for death due to primary liver cancer and death due to

1 drug-related causes. The SMR for liver cancer was less pronounced in the subgroup of patients
2 without diagnosed cirrhosis at baseline (SMR: 9.02; 95% CI: 2.91-27.96), than in the entire SVR
3 cohort as a whole (SMR: 23.50; 95% CI: 12.23-45.16). In contrast, the SMR for drug related mortality
4 was comparable between all SVR patients (SMR: 6.58, 95% CI: 4.15-10.45), and SVR patients
5 without baseline cirrhosis (SMR: 6.90, 95% CI: 4.35-10.96). We did not see any statistically
6 significant differences in the SMRs for liver cancer mortality, all-cause mortality and drug mortality
7 according to age (see Figure 3[i]). Finally, no statistically significant elevations were noted for the
8 remaining cause-specific categories, including: other liver disease; external causes, diseases of the
9 circulatory system; and non-liver cancers.

16 4: THE ABSOLUTE CONTRIBUTION OF EACH CAUSE TO THE OVERALL EXCESS:

18 Drug-related mortality made the biggest absolute contribution to overall excess mortality (42% in all
19 SVR patients, and 75% in SVR patients without baseline cirrhosis). Primary liver cancer accounted
20 for 24% of the total excess in all SVR patients and 13% of the excess in SVR patients without
21 cirrhosis. Taken together, these two causes of death accounted for 66% of all excess deaths in the
22 SVR cohort as a whole, and 88% of all excess death in SVR patients without cirrhosis (see Fig.2). We
23 further examined the absolute contribution of primary liver cancer and drug-related mortality in all
24 SVR patients according to age during follow-up (see Figure 3[ii]). In the under 50s, drug-related
25 causes accounted for the majority of the excess death (53%), whilst the contribution of primary liver
26 cancer was minimal (<5%). Conversely, in the over 50s, most of the excess (54%) was due to liver
27 cancer, whilst drug-related mortality played a more minor role (accounting for only 26% of the
28 excess).

37 5: BASELINE FACTORS ASSOCIATED WITH ALL-CAUSE MORTALITY

40 Ten factors were significantly associated ($p < 0.05$) with an increased risk of post-SVR mortality
41 following adjustment for age group and gender, cirrhosis and CCI; see Table.1. These were as
42 follows: older age; male gender; diagnosis of liver cirrhosis; high Charlson comorbidity score; past
43 alcohol consumption $\geq 50+$ units/wk sustained for six months or more; history of intravenous drug
44 use; past hospitalisation for alcohol intoxication; past hospitalisation for drug intoxication; and past
45 hospitalisation for violence-related injury, and APRI < 0.7 .

51 6: POST-HOC ANALYSES: GENERATING A COMPOSITE SCORE FOR HEALTH RISK 52 BEHAVIOURS

55 The five modifiable factors associated with post-SVR mortality were as follows: 1. past alcohol
56 consumption $\geq 50+$ units/wk sustained for six months or more; 2. history of intravenous drug use; 3.
57 past hospitalisation for alcohol intoxication; 4. past hospitalisation for drug intoxication; and 5. past
58 hospitalisation for violence-related injury.

hospitalisation for violence-related injury heavy alcohol use). In a post-hoc analysis, we generated a 4-point composite score based on the presence or absence of these five factors (see Fig.4). The intention was to create a proxy marker for health risk behaviours present during follow-up. We calculated SMRs for all-cause mortality according to this composite score and observed a strong dose-response relationship (p-value for trend, <0.001). Among all SVR patients with a score of zero (i.e. indicating the minimum level of health risk behaviour), the SMR was 0.70 (95% CI: 0.41-1.18), whereas for individuals with a score of 3 (i.e. the maximum score, indicating the highest level of health risk behaviour), the SMR was 6.19 (95% CI: 3.60-10.67). We also constructed a multivariate Cox regression model to assess the association between our behaviour score and the mortality hazard after adjusting for age, sex, cirrhosis, CCI and APRI (see Table 3). We observed a stepwise change in the mortality hazard according to behaviour score. Among all SVR patients, the hazard was 2.12 times (p=0.035) , 4.25 times (p<0.001), and 7.28 times (p<0.001) higher for individuals with a score of 1, 2 and 3, respectively, relative to individuals with a score of zero.

DISCUSSION:

MAIN FINDINGS:

The arrival of highly effective and tolerable antiviral regimens for chronic hepatitis C infection has set the stage for a rapid increase in the number of persons living with SVR. Yet, our present understanding of the prognosis that this “cured” population face is incomplete. Although we know that SVR patients exhibit superior mortality and morbidity rates relative to non-SVR patients [3, 13, 18], we know little about how these rates compare to the broader general population. In the present study, we followed 1824 SVR patients up for 5.2 years on average, and observed mortality rates in excess of the general population. Specifically, among all SVR patients, mortality rates were almost 2-fold higher (SMR: 1.86; 95% CI: 1.49-2.32), whilst among SVR patients without a diagnosis of cirrhosis at baseline - a group who on the whole will tend to be discharged from specialist care without further follow-up - mortality rates were 1.6-fold higher (SMR: 1.55; 95% CI: 1.20-2.01). Our cause-specific analyses (see Table 2 and Fig.2-3) demonstrated two important points. Firstly, that the overall excess was driven, in the main, by a higher than expected frequency of death from liver cancer and death from drug-related causes. Secondly, that the contribution of these two causes differed with respect to age. Drug-related mortality accounted for 53% of all excess death in the under 50s (in comparison, only 4.3% of the excess death was due to primary liver cancer). Conversely, death from liver cancer accounted for 54% of all excess death in the over 50s (whereas, in this age group, only 26% of the excess death was due to drug-related causes).

THE OCCURRENCE OF PRIMARY LIVER CANCER:

The largest cause-specific SMRs were seen with respect to primary liver cancer. In our SVR cohort as a whole, the risk of dying from liver cancer was more than 20 times greater than the general population (SMR: 23.50; 95% CI: 12.23-45.16). Notably, an excess risk of dying from liver cancer remained - SMR: 9.02; 95% CI: 2.91-27.96 - after excluding individuals with diagnosed liver cirrhosis at baseline. This result requires careful interpretation. On the one hand, it could lend support to previous observations that the risk of liver cancer after SVR is not confined to cirrhotic patients, but extends more widely to some patients at the pre-cirrhosis stage.[24-28] Alternatively, it may reflect a high level of undiagnosed liver cirrhosis in our cohort (indeed, the potential for this is appreciable, given that the majority of patients had no record of a liver biopsy or fibroscan being conducted in the two years prior to baseline – see eTable 4). To inform which interpretation is more valid, we reviewed the medical notes of the three “non cirrhotic” individuals who went on to develop primary liver cancer (involving two deaths from hepatocellular carcinoma and one from intrahepatic bile duct carcinoma). While two patients had indications of significant/severe fibrosis, none of the three would have met the definition of compensated cirrhosis currently adopted by NHS England (see Appendix A), despite all having the requisite tests to do so on at least one level (i.e. all three had an

APRI score and AST:ALT ratio pre-treatment; while one case had an ultrasound and another had a biopsy upon completion of therapy). Further, only one case was retained in on-going clinical follow-up post SVR, while the other two were discharged. More research is arguably needed to inform which SVR patients can be safely discharged, versus which patients would benefit from regular HCC screening. However, we must stress that although the *relative* risk of a liver cancer death was high in the non-cirrhotic group (i.e. nine times higher relative to the general population), the *absolute* risk – both of liver cancer and indeed of any liver-related event - was still very low (<1% after 7.5 years - see eFig.1).

PATIENT CHARACTERISTICS ASSOCIATED WITH POST-SVR MORTALITY:

To understand how the elevated mortality rate in “cured” hepatitis C patients might be reversed, we carried out a regression analysis to identify modifiable predictors of all-cause mortality (see Table.1). Ten predictive characteristics were identified in total, of which half – older age, male gender, liver cirrhosis; high CCI; and APRI <0.7 – were non-modifiable. But the remaining characteristics identified were markers of health risk behaviours (history of injecting drug use, history of heavy alcohol use, and past hospitalisation for violence, drug intoxication or alcohol intoxication) that, in principle at least, can be reversed. We created a composite score to approximate the degree of health risk behaviours present during follow-up (see Fig.4). The strong correlation between this composite score and the all-cause SMR suggests two things. Firstly, that health risk behaviours exert a strong influence on the extent to which mortality exceeds general population levels. Secondly, where health risk behaviours are minimal (i.e. as indicated by a score of zero) all-cause mortality rates are equivalent to and even lower than the general population.

From the non-modifiable predictors identified in this study, the increased mortality risk associated with APRI <0.7 (versus APRI ≥0.7) was unexpected and at first glance paradoxical – see Table 1. Subsequent interrogation revealed however that this association was very cause-specific, being driven only by an increased risk for drug mortality (see eFig.2). The association overall therefore is probably due to residual confounding. Mild disease will be associated with more recent acquisition of HCV (given that fibrosis increases with duration of infection), which in turn will be associated with active drug use. With more robust data on active drug use at baseline, we would therefore not expect an association with APRI<0.7 to persist.

CONSISTENCY WITH PREVIOUS WORK:

Our finding of higher mortality in SVR patients relative to the general population is not supported by two previous studies. In a cohort of 192 SVR patients with F3-F4 fibrosis and an average age of 49 years, Van der Meer et al observed a 10-year survival rate of 91.1%. [17] This was on par with survival in the general population. More recently, Bruno et al reported 10 year survival of 90.9% for

177 SVR cirrhotic patients with a mean age of 59 years. [18] Again, this 10-year survival was comparable to the general population. In contrast, for the present study, we followed up a much larger (N=1824), younger (mean age of 40.7 yrs) and more inclusive (comprising patients across the fibrosis continuum – not just those at an advanced end) group of SVR patients. Conversely, the 10-year survival that we observed of 93.2% was significantly lower than the 96.2% survival expected for the general population taking age, sex and calendar period into account. In overall terms, 86% more deaths were observed during our study than would have been expected under general population mortality rates (i.e. 78 deaths observed versus 42 expected). One possible explanation for the higher mortality rate in our study could be selection bias. The patients in our Scottish cohort represent the vast majority (80%+) of individuals attaining SVR in Scotland over the 1996-2011 time frame of this study. In contrast, the two previous studies were largely made up of individuals with biopsy-proven advanced liver fibrosis that attended a small number of tertiary clinics that may not accurately reflect the wider SVR population. Clearly more studies, from a variety of cohorts, are required to form a complete picture on this issue. Otherwise, our results concur with a prior analysis from Scotland reporting increased hospitalisation rates in SVR patients relative to the general population [29]. Our results are also consistent with a nationwide cohort study from Denmark. [30] In this study, Omland et al observed that individuals who clear HCV infection spontaneously (not via treatment albeit) had higher overall mortality than the general population. However, - in line with this study (see fig.4) - mortality was more comparable to the general population in subgroups without a history of alcohol and drug abuse.

LIMITATIONS OF THIS STUDY:

There are several limitations in this analysis to highlight. Cirrhosis was diagnosed in only 5.8% of patients at baseline, however due to inadequate testing, this is likely to be an underestimate of the true fraction with cirrhosis. Indeed, e-Table 4 shows that only 44% of patients received a liver biopsy or a fibroscan in the two years prior to SVR attainment, which highlights the lack of uniform cirrhosis surveillance in our cohort. Potentially, undiagnosed liver cirrhosis could explain why we observed six liver deaths in our non-cirrhotic group, albeit we think that this is unlikely because when we reviewed the medical notes of the 3 “non-cirrhotic” patients who developed liver cancer, we did not find anything to suggest that these individuals were cirrhotic in reality. Another limitation is that we had no information on the socioeconomic status of patients in this cohort. Because hepatitis C virus infection disproportionately affects people of lower socioeconomic status, and lower socioeconomic status is in turn associated with higher mortality rates [31], the omission of this variable could have inflated our survival differences. Thirdly, our data on health risk behaviours are limited in that they relate only to the baseline time point, and mostly focus on only the extremes of alcohol and drug use. Future studies correcting for these weaknesses and additionally examining the impact of other major health behaviours –tobacco smoking, physical activity and diet—would be valuable. Fourthly,

1 patients in our cohort were treated with either standard interferon ± ribavirin, or pegylated interferon ±
2 ribavirin. These regimens are long (16-48 weeks) and entail significant adverse effects. As a result,
3 patients would typically have received intensive coaching from clinicians and nursing staff (and this
4 coaching would have applied especially to SVR patients who, given futility stopping rules, remain in
5 the treatment window for longer than non-SVR patients). We have previously speculated that this
6 coaching and/or the euphoria of attaining SVR may have an important galvanising effect on patients
7 with regard to encouraging more salubrious health behaviours [19]. Thus, in the impending era of
8 highly tolerable, accessible and efficacious antiviral therapy– i.e. an era that will obviate the same
9 level of patient coaching and patient commitment – a very different post-SVR picture could emerge. It
10 will be important to repeat this analysis five years hence. Finally, we did not have robust data on
11 diabetes mellitus status and obesity despite these conditions being recognised determinants of liver
12 sequelae in the SVR population.[32]

21 SUMMARY:

23 In this large nationwide Scottish cohort, mortality in patients with a hepatitis C “cure” was higher than
24 the general population. The excess was mainly driven by death from liver cancer and death from
25 drug-related causes. Health risk behaviours emerged as the major modifiable risk factor for mortality
26 in this population underlining the importance of a multidisciplinary approach to HCV that addresses
27 lifestyle risk factors *in addition to* viral infection. On this note the SVR time-point may be a
28 particularly opportune moment to assess what other services and support the patient may be in need
29 of. To minimise the post-SVR risk of HCC, careful and prudent staging of liver fibrosis should be
30 performed prior to discharge to identify those patients who might benefit from regular screening.
31 Arguably, more research is needed to bottom out more precisely which SVR patients stand to benefit
32 from such surveillance. As a final aside, this analysis has bearing on the new WHO targets to cut
33 global death from hepatitis B and C by 10% before 2020, and by 65% by 2030 [33].
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES:

- [1] Pawlotsky J-M. New hepatitis C therapies: the toolbox, strategies and challenges. *Gastroenterology* 2014; 146:1176-1192.
- [2] Pawlotsky J-M, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. *J Hepatol* 2015; 62:S87-S99.
- [3] Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. *Clin Infect Dis* 2011;52(7):889-900.
- [4] "Pamela Anderson says: I'm cured of Hep C". Accessed December 2015. <http://www.thesun.co.uk/sol/homepage/showbiz/6732270/Pamela-Anderson-cured-of-Hepatitis-C.html>
- [5] Your moment to cure. Viekira homepage. Accessed January 2016. <https://www.viekira.com/>
- [6] I am hepatitis C cured. Sovaldi homepage. Accessed January 2016. <http://www.sovaldi.com/>
- [7] Hepatitis C virus can be cured in 12 weeks with drug course: study. Accessed December 2015. http://www.huffingtonpost.ca/2015/11/18/hepatitis-c-cure_n_8592704.html
- [8] Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. *Gastroenterology*. 2008; 135:821-9.
- [9] Thein H, Q Yi, Dore GJ, Krahm MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology* 2008; 48(2):418-31.
- [10] El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. *Hepatology* 2002;36:S74-S83.
- [11] Aspinall E, Hutchinson SJ, Janjua NS, Grebley J, Yu A, Alavi M, et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. *J Hepatol* 2015; 62:269-77.
- [12] Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. *Gastroenterology* 2015; 149:1345-60.
- [13] Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. *Clin Infect Dis*. 2015;61:730-740.

- [14] Lambert PC, Thompson JR, Weston CL, Dickman PW. Estimating and modelling the cure fraction in population-based cancer survival analysis. *Biostatistics* 2007; 8:576-94.
- [15] Del Maso L, Guzzinati S, Buzzoni C, Capocaccia R, Serraino D, Caldarella A, et al. Long-term survival, prevalence , and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. *Ann Oncol* 2014; 25:2251-60.
- [16] Van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. *JAMA* 2014; 312:1927-8.
- [17] Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. *J Hepatol* 2016; 64: 1217-23.
- [18] Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat.* 2014; 21 Suppl 1: 34-59.
- [19] Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, et al. Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. *Hepatology* 2015;62:355-64.
- [20] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-383. 20.
- [21] Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43:1130-1139.
- [22] Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet-ratio index for the stage of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology* 2011;53:726-736.
- [23] Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. *Eur J Gastroenterol Hepatol* 2012;24:646-655.
- [24] Sewell JL, Stick KM, Monto A. Hepatocellularcarcinoma after sustained virologic response in hepatitis C patients with cirrhosis on a pretreatment liver biopsy. *Eur J Gastroenterol Hepatol.* 2009; 21:225-9.

- [25] Hirashima N, Mizokami M, Orito E, Koide T, Itazu I, Kamuda K, et al. Case report: development of hepatocellular carcinoma in a patients with chronic hepatitis C infection after a complete and sustained response to interfetron-alpha. *J Gastroenterol Hepatol*. 1996; 11:955-8.
- [26] Scherzer TM, Reddy KR, Wrba F, Hofer H, Staufer K, Steindl-Munda P, et al. Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C. *J Viral Hepat*. 2008; 15: 659-65.
- [27] Tabibian JH, Landaverde C, Winn J, Geller SA, Nissen NN. Hepatocellular carcinoma in a hepatitis C patients with sustained viral response and no fibrosis. *Ann Hepatol*. 2009; 8:64-67.
- [28] Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. *J Gastroenterol Hepatol*. 2015; doi: 10.1111/jgh.13236
- [29] Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, et al. Excess liver-related morbidity of chronic hepatitis C patients who achieve a sustained viral response and are discharged from care. *Hepatology* 2011; 54:1547-58.
- [30] Omland LH, Christensen PB, Krarup H, Jepson P, Weis N, Sorensen HT, et al. Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study. *PLoS One*. 2011; 6:e22476.
- [31] Omland LH, Osler M, Jepsen P, Krarup H, Weis N, Christensen PB, et al. Socioeconomic status in HCV infected patients – risk and prognosis. *Clin Epidemiol* 2013; 5:163-72.
- [32] El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. *Hepatology* 2016; in press
- [33] Stephan Wiktor. Hepatitis B and C public policy association meeting: EU HCV Brussels, 17th February 2016. <http://www.hcvbrusselssummit.eu/material/summit-podcast> (accessed April 2016).

FIGURE LEGENDS:

Fig.1: Ten-year survival relative to the general population for: (i) all SVR patients; and (ii) SVR patients without cirrhosis.

Fig.2: Absolute contribution (%) to the overall excess for each cause of death, for (i) all SVR patients, and (ii) SVR patients without cirrhosis at baseline.

Fig.3: For all SVR patients: (i) cause-specific standardised mortality ratios according to age, and (ii) absolute contribution (%) to the overall excess for each cause of death, according to age.

Fig.4: Standardised mortality ratio according to baseline health risk behaviours, for (i) all SVR patients, and (ii) SVR patients without cirrhosis.

TABLE 1: Baseline characteristics associated with post-SVR mortality, for: (I) all SVR patients; and (II) SVR patients without cirrhosis at baseline

Category	Variable		(I) ALL SVR PATIENTS; (N=1824)				(II) SVR PATIENTS WITHOUT BASELINE CIRRHOSIS; (N=1717)			
			Number (col %)	Deaths	Crude hazard ratio (95 % CI)	Adjusted hazard ratio (95 % CI) †	Number (col %)	Deaths	Crude hazard ratio (95 % CI)	Adjusted hazard ratio (95 % CI)‡
Basic demographics	(i) Age group	<35 yrs	542 (29.7)	11	REF (1.00)	REF (1.00)	538 (31.3)	11	REF (1.00)	REF (1.00)
		35-49yrs	976 (53.5)	41	2.14 (1.10-4.16)*	1.79 (0.91-3.54)	922 (53.7)	33	1.82 (0.92-3.61)	1.73 (0.87-3.46)
		50+yrs	306 (16.8)	26	4.28 (2.11-8.68)***	2.76 (1.31-5.84)**	257 (15.0)	14	2.74 (1.24-6.06)*	2.55 (1.15-5.69)*
	(ii) Gender	Female	585 (32.1)	12	REF (1.00)	REF (1.00)	556 (32.4)	10	REF (1.00)	REF (1.00)
		Male	1239 (67.9)	66	2.75 (1.49-5.09)**	2.58 (1.39-4.79)**	1161 (67.6)	48	2.45 (1.24-4.85)*	2.44 (1.23-4.82)*
Medical co-morbidities	(iii) Diagnosed with cirrhosis	No	1717 (94.1)	58	REF (1.00)	REF (1.00)	1717 (100.0)	58	\	\
		Yes	107 (5.9)	20	5.34 (3.21-8.89)***	3.11 (1.72-5.60)***	0 (0.0)	0	\	\
	(iv) Charlson co-morbidity index	None (0)	993 (54.4)	30	REF (1.00)	REF (1.00)	966 (56.3)	27	REF (1.00)	REF (1.00)
		Medium (1-2)	758 (41.6)	35	1.04 (0.64-1.72)	0.87 (0.53-1.45)	704 (41.0)	26	0.92 (0.53-1.60)	0.85 (0.49-1.48)
High (3+)		73 (4.0)	13	5.27 (2.75-10.13)***	2.35 (1.13-4.90)*	47 (2.7)	5	3.33 (1.28-8.68)*	2.84 (1.08-7.45)*	
Viral genotype	(v) Genotype	non-3	612 (33.6)	27	REF (1.00)	REF (1.00)	582 (33.9)	22	REF (1.00)	REF (1.00)
		3	1130 (62.0)	44	0.80 (0.50-1.30)	0.77 (0.47-1.25)	1057 (61.6)	30	0.69 (0.40-1.20)	0.73 (0.42-1.28)
		Missing	82 (4.5)	7	0.88 (0.37-2.10)	0.99 (0.41-2.37)	78 (4.5)	6	0.97 (0.38-2.50)	1.04 (0.40-2.67)
Health risk behaviours	(vi) Maximum units/wk alcohol sustained for at least six months	<21	1378 (75.6)	45	REF (1.00)	REF (1.00)	1321 (76.9)	39	REF (1.00)	REF (1.00)
		22-49	116 (6.4)	4	0.93 (0.33-2.58)	0.66 (0.23-1.86)	107 (6.2)	2	0.57 (0.14-2.35)	0.49 (0.12-2.06)
		50+	330 (18.1)	29	3.02 (1.89-4.82)***	2.12 (1.30-3.47)**	289 (16.8)	17	2.25 (1.27-3.99)**	1.91 (1.07-3.43)*
	(vii) History of intravenous drug use	No	756 (41.5)	25	REF (1.00)	REF (1.00)	703 (40.9)	12	REF (1.00)	REF (1.00)
		Yes	1068 (58.6)	53	1.75 (1.09-2.82)*	2.36 (1.41-3.94)**	1014 (59.1)	46	3.14 (1.66-5.94)***	3.41 (1.77-6.56)***
	(viii) Past hospitalisation for alcohol intoxication	No	1699 (93.2)	65	REF (1.00)	REF (1.00)	1604 (93.4)	48	REF (1.00)	REF (1.00)
		Yes	125 (6.9)	13	3.25 (1.79-5.90)***	3.17 (1.72-5.85)***	113 (6.6)	10	3.49 (1.76-6.91)***	3.42 (1.71-6.82)***
	(viii) Past hospitalisation for violence-related injury	No	1503 (82.4)	58	REF (1.00)	REF (1.00)	1415 (82.4)	43	REF (1.00)	REF (1.00)
		Yes	321 (17.6)	20	2.01 (1.21-3.35)**	1.88 (1.10-3.20)*	302 (17.6)	15	2.05 (1.14-3.71)*	1.84 (1.00-3.40)*
	(x) Past hospitalisation for drug intoxication	No	1563 (85.7)	58	REF (1.00)	REF (1.00)	1468 (85.5)	39	REF(1.00)	REF (1.00)
		Yes	261 (14.3)	20	2.34 (1.41-3.90)**	2.87 (1.68-4.89)***	249 (14.5)	19	3.26 (1.88-5.65)***	3.59 (2.01-6.41)***
Liver Function Tests	(xi) Mean aspartate aminotransferase-to-platelet ratio-index	<0.7 (~mild fibrosis)	639 (35.0)	24	REF (1.00)	REF (1.00)	632 (36.8)	22	REF (1.00)	REF (1.00)
		≥0.7 (~ non-mild fibrosis)	553 (30.3)	21	0.85 (0.47-1.52)	0.50 (0.27-0.94)*	496 (28.9)	12	0.58 (0.29-1.18)	0.51 (0.25-1.03)*
		Missing	632 (34.7)	33	1.11 (0.66-1.89)	0.76 (0.43-1.32)	589 (34.3)	24	0.96 (0.53-1.71)	0.87 (0.48-1.57)
	(xii) Mean Gamma-Glutamyl Transferase before treatment (IU/l)	<55	933 (51.2)	26	REF (1.00)	REF (1.00)	913 (53.2)	24	REF (1.00)	REF (1.00)
		≥55	610 (33.4)	33	2.16 (1.29-3.62)**	1.30 (0.76-2.24)	536 (31.2)	18	1.41 (0.76-2.59)	1.13 (0.61-2.09)
		Missing	281 (15.4)	19	2.17 (1.20-3.95)*	1.68 (0.92-3.09)	268 (15.6)	16	2.03 (1.07-3.84)*	1.78 (0.93-3.38)
† multivariate adjustment for : 1. age group ; 2. gender, 3. Charlson Comorbidity Index, 4. liver cirrhosis										
‡ multivariate adjustment for : 1. age group ; 2. gender, 3. Charlson Comorbidity Index										
* denotes p-value ≤0.05										
** denotes p-value <0.01										
*** denotes p-value <0.001										

Table.2 Cause-specific standardised mortality ratios (SMR) relative to the general population of Scotland, for: (I) for all SVR patients; and (II) SVR patients without cirrhosis at baseline.

#	Cause of death	(I) All SVR patients (N=1824)			(II) SVR patients without cirrhosis (N=1717)		
		# expected deaths	# observed deaths	SMR (95% CI)	# expected deaths	# observed deaths	SMR (95% CI)
1	Primary liver cancer	0.4	9	23.50 (12.23-45.16)	0.3	3	9.02 (2.91-27.96)
2	Other liver-related (excluding liver cancer)	3.1	7	2.25 (1.07-4.71)	2.8	3	1.06 (0.34-3.30)
3	Drug-related	2.7	18	6.58 (4.15-10.45)	2.6	18	6.90 (4.35-10.96)
4	External causes	4.0	5	1.27 (0.53-3.04)	3.7	4	1.09 (0.41-2.89)
5	Non liver cancer	12.6	16	1.27 (0.78-2.08)	11.0	14	1.28 (0.76-2.15)
6	Disease of the circulatory system	10.2	9	0.89 (0.46-1.70)	8.9	8	0.90 (0.45-1.79)
7	Other (i.e. none of the above)	9.1	14	1.54 (0.91-2.61)	8.1	8	0.99 (0.50-1.99)
1-2	All liver-r related	3.5	16	4.57 (2.80-7.46)	3.2	6	1.90 (0.86-4.24)
3-7	All non-liver related	38.5	62	1.61 (1.26-2.07)	34.2	52	1.52 (1.16-2.00)
1-7	All-causes	42.0	78	1.86 (1.49-2.32)	37.4	58	1.55 (1.20-2.01)

Table 3: Multivariate model including health risk behaviour composite score, for (i)all SVR patients (N=1824); (ii) SVR patients without cirrhosis (N=1717).

Category	Variable		(I) All SVR patients (N=1824)		(II) SVR patients without cirrhosis (N=1717)	
			Adjusted hazard ratio (95 % CI)	p-value	Adjusted hazard ratio (95 % CI)	p-value
Composite health risk behaviour score	0 (most favourable)		REF (1.00)	\	REF (1.00)	\
	1		2.12 (1.05-4.25)	0.035	3.74 (1.47-9.57)	0.006
	2		4.25 (2.15-8.41)	<0.001	7.22 (2.89-18.05)	<0.001
	3 (least favourable)		7.28 (3.29-16.08)	<0.001	10.42 (3.54-30.68)	<0.001
Basic demographics	(i) Age group	<35 yrs	REF (1.00)	\	REF (1.00)	\
		35-49yrs	1.60 (0.81-3.18)	0.177	1.58 (0.46-1.49)	0.197
		50+yrs	3.80 (1.80-8.01)	<0.001	3.32 (1.48-7.46)	0.004
	(ii) Gender	Female	REF (1.00)	\	REF (1.00)	\
		Male	2.11 (1.12-3.94)	0.020	1.82 (0.91-3.64)	0.089
Medical co-morbidities	(iii) Diagnosed with cirrhosis	No	REF (1.00)	\	\	\
		Yes	3.31 (1.81-6.02)	<0.001	\	\
	(iv) Charlson co-morbidity index	None (0)	REF (1.00)	\	REF (1.00)	\
		Medium (1-2)	0.88 (0.52-1.46)	0.614	0.89 (0.51-1.55)	0.67
		High (3+)	3.01 (1.44-6.26)	0.003	3.45 (1.31-9.09)	0.012
Liver Function Tests	(xi) Mean aspartate aminotransferase-to-platelet ratio-index	<0.7 (mild fibrosis)	REF (1.00)	\	REF (1.00)	\
		≥0.7 (non-mild fibrosis)	0.49 (0.26-0.92)	0.025	0.50 (0.25-1.02)	0.058
		Missing	0.73 (0.42-1.27)	0.269	0.83 (0.46-1.49)	0.525

Fig.1 Ten-year survival relative to the general population for: (I) all SVR patients; and (II) SVR patients without cirrhosis

Fig.2 Absolute contribution (%) to the overall excess for each cause of death, for (i) all SVR patients, and (ii) SVR patients without cirrhosis at baseline

Fig.3: For all SVR patients: (i) cause-specific standardised mortality ratios according to age, and (ii) absolute contribution (%) to the overall excess for each cause of death, according to age

Fig.4: Standardised mortality ratio according to baseline health risk behaviours, for (I) all SVR patients; and (II) SVR patients without cirrhosis

Mortality in a nationwide cohort of SVR patients relative to the general population

All patients (N=1824)

Standardised Mortality Ratio: 78/42
= **1.86 (95% CI: 1.49-2.32)**

Patients not diagnosed with cirrhosis (N=1717)

Standardised Mortality Ratio: 58/37
= **1.55 (95% CI: 1.20-2.01)**